Bradley Stish (@DrStish) profile picture

GU Radiation Oncologist @ Mayo Clinic, Minnesota Gophers fan, Father of three. Obsessed with finding the perfect IPA. Views are solely my own

Minnesota, USA
Joined June 2017
Photo by Bradley Stish (@DrStish)Photo by Bradley Stish (@DrStish)Photo by Bradley Stish (@DrStish)Photo by Bradley Stish (@DrStish)Photo by Bradley Stish (@DrStish)Photo by Bradley Stish (@DrStish)Photo by Bradley Stish (@DrStish)Photo by Bradley Stish (@DrStish)Photo by Bradley Stish (@DrStish)Photo by Bradley Stish (@DrStish)
Can we use multi-stage pipeline integrating automatic speech recognition, speaker diarization and large language models to automate CTCAE scoring from ambient audio? We sure can! 👇🏼👇🏼 Check out our department's new work! nature.com/articles/s41746-0… @FMastroleoMD @WaddleMd
6
8
432
Excited to share the early feasibility and dosimetric results from our prospective trial of 5 fraction post-prostatectomy SBRT. CBCT based online adaptive treatment facilitated use of a modified reduced volume CTV and PTV (3 mm) w/many pts getting up LN and simultaneous boosts.
📌 Feasibility and Dosimetric Outcomes of CT-Based Daily Adaptive SABR in Patients Receiving Salvage Treatment for Biochemical Recurrence of Prostate Cancer 🔗 advancesradonc.org/article/S… ☢️Single-center phase II DAPPER study: 50 patients with biochemical recurrence after prostatectomy received CT-based daily adaptive SABR to the prostate fossa ± pelvic nodes (5 fx). 👉 Feasibility: 98% of fractions (246/250). 👉 Plan selection: Adaptive plans selected in 89% of fractions. 👉 Dosimetric outcomes: Improved target coverage and reduce bowel and rectal V25Gy. @ASTRO_org @DrStish @WaddleMd @EricLehrer @RomanKowalchuk @MayoRadOnc
1
4
18
1,131
📌 Feasibility and Dosimetric Outcomes of CT-Based Daily Adaptive SABR in Patients Receiving Salvage Treatment for Biochemical Recurrence of Prostate Cancer 🔗 advancesradonc.org/article/S… ☢️Single-center phase II DAPPER study: 50 patients with biochemical recurrence after prostatectomy received CT-based daily adaptive SABR to the prostate fossa ± pelvic nodes (5 fx). 👉 Feasibility: 98% of fractions (246/250). 👉 Plan selection: Adaptive plans selected in 89% of fractions. 👉 Dosimetric outcomes: Improved target coverage and reduce bowel and rectal V25Gy. @ASTRO_org @DrStish @WaddleMd @EricLehrer @RomanKowalchuk @MayoRadOnc
5
2
10
2,098
Bradley Stish retweeted
Trial protocol for the TRITONS trial 🔱 Any solid malignancy with 1-10 metastases. Starting new line of systemic therapy. Randomize +/- SABR to mets. We are learning! Underway @UCSDCancer @UCSDHealth. Pending in 🇩🇰 @andreasroder1 @DrRanaMcKay @medmund14
Total RadIoTherapy of Oligometastatic caNcerS (TRITONS): International Phase III Trial Protocol of Stereotactic Ablative Radiotherapy for ≤10 Metastases with Systemic Therapy. Co-authored by @tylersbrt. Read the full article. bit.ly/4zzWlgz
3
17
1,000
Bradley Stish retweeted
So blessed to have the support of @MayoRadOnc and multiple donors to help make this happen!
Mayo Clinic researchers are studying whether low-dose radiation therapy can slow the progression of Parkinson's disease by targeting inflammation in areas of the brain affected by the disease. The clinical trial is the first to investigate low-dose radiation as an anti-inflammatory approach in patients with early-stage Parkinson's disease. Learn more: mayocl.in/4hX0IMP
1
1
18
613
Bradley Stish retweeted
8/ The Emperor's new clothes was a tale of the masses one by one being pressured to believe the emperor had new clothes, when he was in fact naked. It was a child who stated the truth. To those who will relfectively push back and use FT off trial, you represent the emperor's courtier. I commend those, especially in urology, willing to respresent the child and bring truth to this concerning practice far ahead of its evidence...especially those who push for evidence. If you care about patients you will do the trials needed to determine if FT helps more than harms, as the early signals remain concerning. I am lucky to have such an amazing team at @CaseUrology. @LPonsky @DrChoueiri @ASTRO_org @alison_tree @AmarUKishan @neerajaiims @Adam_Weiner535 @DrStish @LauraBukavinaMD @SbrtSean @ASTRO_Chair @ChadTangMD @DrAndrewLoblaw @DrOmarMian @StephDudzinski @UroCancer @EUplatinum @alongi_filippo @PGrivasMDPhD @shilpaonc @wandering_gu @HimanshuNagarMD @TripleH @jryckman3 @jamecancerdoc @NicholasZaorsky @TylerSbrt @AmandaNizamMD @piet_ost @QuadShotNews @qdtrinh @Soum_Roy_RadOnc @rweichselbaum @_ShankarSiva @urotoday @VPrasadMDMPH @VedangMurthy @NehaVapiwala @z
2
9
1,153
Bradley Stish retweeted
This work was led by @xinformatics with David Routman in Mayo Clinic’s Radiation Oncology AI & Data Analytics team. Interested in applying AI to practical medical problems? We’re hiring AI/ML research fellows and interns. Check here for updates: andrewfoongyk.github.io/#hir…
3
5
225
Bradley Stish retweeted
A new publication reports a 30-day mortality of 11% among nearly 1,000 pts who underwent histotripsy for primary and metastatic liver tumors. This statistic signals a need for greater scrutiny to clarify the utility and practice patterns of this supposedly "less invasive" treatment. jamanetwork.com/journals/jam…
6
27
1
65
16,064
Bradley Stish retweeted
Are you a medical oncologist or an oncology fellow with interest in GI Oncology? Would you like to work at a world renowned large medical center in Minnesota? With a phenomenal multidisciplinary team...? And with lots of research opportunities...? If so, we have an open position in GI Oncology at Mayo Clinic in Rochester. Check it out below and apply if interested... Also, please forward/tag anyone who may have interest. Happy to take questions if you have any having worked here for over 15 years. jobs.mayoclinic.org/job/roch…
1
16
38
3,062
Bradley Stish retweeted
Prospective trial 68 patients MRI confirmed refractory chronic plantar fasciitis - LDRT 3Gy/6 - Significant pain relief out to 2 yrs - Improvements function, QOL - 96% had pain & 99% functional response rate
4
24
2
61
3,687
Great thread discussing the role of TMT as an alternative option to cystectomy.
Replying to @UroDocAsh
/1 Shared decision making is only shared decision making when patients are informed of all their choices. As we showed in our global patient survey, the majority of patients are never told there is any option other than radical cystectomy. You cannot call it a choice if only one path was ever offered. @siadaneshmand @WorldBladderCan @pjhensley11 @UroCancer @TylerSbrt @niyatilobo
1
13
1,795
Bradley Stish retweeted
I’m making the 600+ slides for my "Intro to Deep Learning" course at Mayo Clinic publicly available here: andrewfoongyk.github.io/#int…
6
77
1
480
22,696
Bradley Stish retweeted
Local salvage therapies alone for #ProstateCancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients. ja.ma/4aQLVz6
13
2
21
4,924
Bradley Stish retweeted
In fact never done this. Has not been a criteria for any of our chemoRT studies, nor is it done much out of trials. Pts will have had a diagnostic TUR only
Replying to @Prof_Nick_James
Do you still do a maximal TURB before chemoRT?
3
7
20
7,150
Bradley Stish retweeted
This was a funded phase 2 study and met its pre-determined endpoint. Highlights that very high rates of bladder preservation possible with adding IO to chemoRT (Note, not TMT - no debulking required)
2
4
16
3,455
Important thoughts when placing these data into the current literature. Will be nice to have ENZARAD published for full details, but clearly learning who benefits from ARPI and who doesn’t is key question going forward.
The real question is the Enzarad data, which is not a subgroup analysis like STAMPEDE. STAMPEDE is hands down my favorite trial ever, but important to note that the M0 analysis was a subgroup analysis and not all patients even had local therapy. Some patients had PSAs in the 1000s. Enzarad a bit more relevant where MFS and OS were not significantly improved in N0M0 patients. Just like PROTEUS MFS and OS were not improved by conventional imaging. Given we now often get PSMA PET/CT upfront for staging, ARPIs in N0M0 patients have no proven role.
1
6
1,448
Bradley Stish retweeted
The real question is the Enzarad data, which is not a subgroup analysis like STAMPEDE. STAMPEDE is hands down my favorite trial ever, but important to note that the M0 analysis was a subgroup analysis and not all patients even had local therapy. Some patients had PSAs in the 1000s. Enzarad a bit more relevant where MFS and OS were not significantly improved in N0M0 patients. Just like PROTEUS MFS and OS were not improved by conventional imaging. Given we now often get PSMA PET/CT upfront for staging, ARPIs in N0M0 patients have no proven role.
1
21
1
43
7,390
Bradley Stish retweeted
Yes, 🔑 takeaways from PROTEUS ✅ amazing to see this level of phase 3 RCT data in a surgical trial 👏🏻👏🏻 ✅ correlative science will be fascinating ❌ results not sufficient to rec peri-op ADT+apa to patients eligible for RT (intact or post-op)
11/n #ASCO26 In summary, congrats to a large well conducted trial. Amazing team. The take home message to me is that the addition of 1 year of ADT+Apa to RP improves BCR and EFS as expected, which can be captured in PET-based MFS which they changed their primary endpoint to include. No data has been shown with large enough effect sizes to believe this will ever translate into conventional imaging MFS, or more importantly OS signals, to make me excited about this for patients. Does a man want 1 year of ADT/ARPI+RP and still high rates of post-op RT+ADT....when they can now simply get RT+ADT without any ARPI based on Enzarad? @prostatemd @SbrtSean @PCF_select @urotoday @ASCO @AmarUKishan @Soum_Roy_RadOnc @CaPsurvivorship @wandering_gu @ChapinMD @SeanMcGuireMD @seanmmcbride @TylerSbrt @HimanshuNagarMD @DrPaulNguyen @DrHowardSandler @aleberlin2 @neerajaiims @ChadTangMD @DrMLChua
5
24
1,770
TBCRC-053 PRAD shows interesting proof of concept for preoperative immune-priming RT with pembrolizumab #ASCO26 @OncoAlert
1
16
19
1,181
Congrats @AtishChoudhury 👉Can we safely de-intensify Rx in exceptional responders with mHSPC/ mAPMS #prostatecancer ? #ASCO2026 A-DREAM data👉Rx holiday after ADT + ARPI may be feasible, with 41% remaining treatment-free with testosterone recovery at 18 mos @OncoAlert @urotoday
1
36
66
4,052